Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | OSBP | P22059 | 1/20 | 0.30 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14511538 | 0.83 | OSBP (0.31) | OSBPOSBP2 | |
| SCHEMBL12118788 | 0.78 | TSHR (0.40) | CHRM2CHRM4CHRM1CHRM3TSHR | |
| SCHEMBL567667 | 0.78 | TSHR (0.40) | CHRM2CHRM4CHRM1CHRM3TSHR | |
| SCHEMBL2326051 | 0.78 | CHRM2 (0.46) | CHRM2CHRM4CHRM1CHRM3SERPINE1 | |
| SCHEMBL2325790 | 0.78 | CHRM2 (0.46) | CHRM2CHRM4CHRM1CHRM3SERPINE1 | |
| SCHEMBL2325787 | 0.78 | CHRM2 (0.46) | CHRM2CHRM4CHRM1CHRM3SERPINE1 | |
| SCHEMBL2325783 | 0.78 | CHRM2 (0.46) | CHRM2CHRM4CHRM1CHRM3SERPINE1 | |
| SCHEMBL5200339 | 0.77 | BTK (0.37) | MEN1KMT2A | |
| SCHEMBL11087055 | 0.77 | SMN1; SMN2 (0.37) | CHRM2CHRM4CHRM3 | |
| SCHEMBL14141238 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786913-B1 | METHOD FOR THE PRODUCTION OF DIARYLCYCLOALKYL DERIVATIVES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2011-08-17 | — | — | EP | disclosed |
| US-7803950-B2 | Method for the production of diarylcycloalkyl derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-09-28 | — | — | US | disclosed |
| US-7803950-B2 | Method for the production of diarylcycloalkyl derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-09-28 | — | — | US | disclosed |
| US-20080051583-A1 | NOVEL INTERMEDIATE COMPOUNDS USEFUL IN THE PRODUCTION OF DIARYLCYCLOALKYL DERIVATIVES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-28 | — | — | US | disclosed |
| US-20080051583-A1 | NOVEL INTERMEDIATE COMPOUNDS USEFUL IN THE PRODUCTION OF DIARYLCYCLOALKYL DERIVATIVES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-28 | — | — | US | disclosed |
| US-20070197614-A1 | METHOD FOR THE PRODUCTION OF DIARYLCYCLOALKYL DERIVATIVES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| US-20070197614-A1 | METHOD FOR THE PRODUCTION OF DIARYLCYCLOALKYL DERIVATIVES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051583-A1 | NOVEL INTERMEDIATE COMPOUNDS USEFUL IN THE PRODUCTION OF DIARYLCYCLOALKYL DERIVATIVES | PPARG, PPARD, PPARA | CHRM2 820/4885CHRM4 1039/4885CHRM1 1219/4885 |
| US-20070197614-A1 | METHOD FOR THE PRODUCTION OF DIARYLCYCLOALKYL DERIVATIVES | PPARA, PPARD, PPARG | CHRM2 284/4885CHRM4 487/4885CHRM1 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.